C-005 Citrate Tablet Dissolution Variability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The pharmaceutical compound C-005 exhibits pH-dependent solubility, leading to variability in absorption due to precipitation in the gastrointestinal tract, causing inconsistent drug absorption rates and amounts between doses and patients, which complicates effective drug delivery and increases safety risks.
Innovation Solution
A pharmaceutical tablet composition is developed with a specific formulation including C-005 citrate, microcrystalline cellulose, crospovidone, and solubilizers like sodium lauryl sulfate, optimized to achieve rapid and complete dissolution within 15-20 minutes at physiologically relevant pH levels, ensuring consistent drug release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If C-005 is administered as a simple blend in capsule, then the formulation is simple to manufacture, but the dissolution is slow and incomplete leading to high variability in drug absorption
Solution Approach 1:
The patent applies preliminary action by pre-forming granules with specific properties before final tablet compression. The granulation process prepares the drug substance in advance with optimized dissolution characteristics, ensuring consistent drug release when the tablet is administered. This pre-preparation of granules with controlled porosity and composition resolves the absorption variability issue while maintaining manufacturing efficiency.
Solution Approach 2:
The patent uses composite materials by combining C-005 with specific excipients including microcrystalline cellulose, crospovidone, and solubilizers in a granulated matrix. This composite formulation enhances dissolution and absorption consistency compared to simple blending, while the granulation process integrates these components into a unified structure that maintains manufacturing simplicity.
2Productivity
If the tablet uses high amounts of disintegrant to improve dissolution speed, then the drug release is faster, but the tablet hardness decreases and manufacturing becomes difficult
Solution Approach 1:
The patent applies parameter changes by optimizing the disintegrant content within a specific range (5-20 wt%) and adjusting granulation parameters such as binder concentration and drying conditions. These parameter optimizations achieve fast dissolution through improved granule porosity and surface area while maintaining adequate tablet hardness for manufacturing, avoiding the need for excessive disintegrant that would compromise structural integrity.
Solution Approach 2:
The granulation process performs preliminary action by pre-establishing the porous structure and surface characteristics of the drug matrix before compression. This pre-formed granule structure facilitates rapid drug release upon contact with gastrointestinal fluids while the granules themselves maintain sufficient mechanical strength to form hard tablets during compression.
3Reliability
If the tablet is designed for rapid dissolution to reduce absorption variability, then the drug release is faster and more consistent, but the manufacturing process becomes more complex
Solution Approach 1:
The patent uses preliminary action through the granulation step that pre-preves the drug matrix with optimized dissolution properties. By performing this preparation in advance, the subsequent compression and coating steps become straightforward, achieving rapid and consistent drug release without requiring complex multi-step manufacturing processes or specialized equipment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The tablet composition achieves high and rapid drug release, reducing inter-dose and inter-patient variability in drug absorption, enhancing drug efficacy and safety by maintaining stable drug levels in systemic circulation.
Implementation Method 1
pharmaceutical composition comprising: (a) from 3 to 70 parts by weight of C-005 citrate; (b) from 5 to 95 parts by weight of a pharmaceutical diluent; (c) from 0.5 to 50 parts by weight of a pharmaceutical disintegrant; (d) from 0 to 5 parts by weight of a pharmaceutical solubilizer
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present disclosure belongs to the field of pharmaceutical preparations, and discloses a pharmaceutical composition and a preparation method therefor and uses thereof. The pharmaceutical composition comprising EGFR inhibitor (C-005) and the pharmaceutical tablets prepared therefrom of the present disclosure are suitable for the treatment of cancer, preferably lung cancer, particularly non-small cell lung cancer.